ライフサイエンスコーパス: multitarget

1 nical small molecules are low-potency and/or multitargeted.

2 esistance-resistant antibiotics that involve multitargeting.

3 harmacological evaluation of a new family of multitarget 2,4-dihydropyrano[2,3-c]pyrazoles as dual GS

4 assifying them as some of the 50 most potent multitarget ABC transporter inhibitors.

5 ) was implemented for the discovery of novel multitarget ABCB1 (P-gp), ABCC1 (MRP1), and ABCG2 (BCRP)

6 considered candidates for further exploring multitarget activities and the molecular basis of polyph

7 veral derivatives of carprofen, sharing this multitarget activity.

8 his non-ATP competitive kinase inhibitor has multitargeted activity, promoting mitotic arrest and apo

9 m of this work was to develop a new class of multitarget agents active both as broad-spectrum antivir

10 eimer's disease calls for the development of multitarget agents addressing key pathogenic processes.

11 NF-kappaB activation and their regulation by multitargeted agents in contrast to monotargeted agents,

12 -steroid sulfatase inhibitors (DASIs) and as multitargeting agents for hormone-independent tumors, su

13 not detected by either noninvasive test, the multitarget analysis of fecal DNA detected a greater pro

14 of adverse events did not differ between the multitarget and intravenous cyclophosphamide groups (50.

15 assigned to receive for 24 months either the multitargeted and FLT3-kinase inhibitor sorafenib (n = 4

16 Both multitargeted and highly selective kinase inhibitors are

17 ween reducing the emergence of resistance by multitargeting and broad-spectrum antibacterial activity

18 Here, we describe single-cell multitargets and mRNA sequencing (scMTR-seq), a high-thr

19 pplied a newly developed and easy to deploy, multitarget, and high-throughput glycomic analysis to ba

20 22584 (PTK/ZK; vatalanib), an orally active, multitargeted angiogenesis inhibitor, has shown tolerabi

21 We report the identification of multitarget anti-Alzheimer compounds designed by combini

22 Multitarget antiangiogenic tyrosine kinase inhibitors (T

23 ation of more than one bioactive moiety in a multitargeted anticancer agent may result in synergistic

24 tive flavonol ligands with the aim to obtain multitargeted anticancer agents.

25 is important for development of efficacious multitargeted anticancer drugs.

26 Multitargeted antifolate (MTA) is an investigational age

27 9 colon carcinoma cells was decreased by the multitargeted antifolate (MTA), LY231514.

28 cal isosteric C8-N9 bridged analogues of the multitargeted antifolate LY231514 were synthesized as in

29 Pemetrexed is a multitargeted antifolate with manageable toxicity and ha

30 ill potentiate the activity of pemetrexed, a multitargeted antifolate, in squamous cell carcinoma of

31 nsideration of hybrid compounds as potential multitarget antimalarials.

32 n contribute to the development of covalent, multitarget antipyroptotic compounds targeting molecular

33 Thus, in search of a multitarget antivascular treatment strategy for AML, we

34 Hence, we propose this multitarget approach as a new and promising strategy for

35 The multitarget approach has gained increasing acceptance as

36 The multitarget approach in drug design is a powerful strate

37 An innovative multitarget approach is presented, targeting both voltag

38 ects of FXR activation appear as a promising multitarget approach.

39 n metastatic prostate cancer will comprise a multitargeted approach aimed at both the tumor cell and

40 A more direct means by which this multitargeted approach can be achieved is by identifying

41 Here, we investigated a multitargeted approach combining exopolysaccharide (EPS)

42 everal pro-permeability proteins providing a multitargeted approach in RVO.

43 A multitargeted approach involving selective local antiang

44 which we are moving from a single- toward a multitargeted approach.

45 eview, we have endeavored to showcase how a "multitargeted" approach to drug design has led to new fa

46 In recent years, multitarget approaches directed toward inhibition of kin

47 developments in immunotherapy for cancer and multitarget approaches in neovascular eye disease.

48 volved in epileptogenesis, it is likely that multitargeted approaches are required for epilepsy preve

49 esponse supports the concept of combination, multitargeted approaches rather than traditional chemoth

50 The multitarget assay is useful as a diagnostic tool to conf

51 rdetella species isolates were tested in the multitarget assay.

52 Small trials of multitarget assays demonstrate a sensitivity for colorec

53 values, both of which were quantified with a multitarget bacterial disinfection model.

54 ducers, thus demonstrating the potential for multitarget biosensing and high-throughput/high-content

55 due to its exceptional biocompatibility and multitargeting capability via sulfur(VI) fluoride exchan

56 origin of patients suggest that sorafenib's multitarget capacity, including RAF kinase inhibition, m

57 This strategy, using multitarget carousel oblique angle deposition, offers th

58 c drugs from PnV molecules may lead to a new multitarget chemotherapy.

59 Our data indicate that multitargeted combinatorial therapies targeting tumor ce

60 e solved if a therapeutic agent could have a multitarget, combinatorial selectivity, killing, or othe

61 Multitargeted complexes which have been designed to targ

62 The "multitargeted" complexes described herein not only targe

63 stallography, or fragment-based design equip multitarget compound development with valuable tools.

64 BMS-794833, a multitargeted compound, was identified as a potent inhib

65 M344 therefore serves as an example of how a multitargeting compound could be used to address the pol

66 We have recently reported the discovery of multitarget compounds able to "kill two birds with one s

67 ination of both activities in this family of multitarget compounds confers them a notable interest fo

68 Synthetic triterpenoids are multitarget compounds exhibiting promise as preventative

69 Development of multitarget compounds is a promising strategy to avoid t

70 A new class of multitarget compounds was synthesized by linking a novel

71 ew insights on the action mechanism of these multitarget compounds, which induce markedly improved pa

72 pounds emerge as interesting brain-permeable multitarget compounds, with a potential as anti-Alzheime

73 m single-target small molecule inhibitors to multitarget compounds.

74 eatment can be reduced by the application of multitarget compounds.

75 Herein we report on a novel series of multitargeted compounds obtained by linking together gal

76 is, and therapeutic effects of the family of multitargeted compounds that simultaneously disrupt func

77 Multitargeting compounds comprising activity on more tha

78 We develop multitargeted degraders to answer fundamental questions

79 the development of a universal nanopore for multitarget detection.

80 erefore, this also allows the development of multitarget devices using porous material for capturing

81 ns, our system offers a general approach for multitarget diagnostics at the point-of-care.

82 espread utility in point-of-care devices and multitarget diagnostics.

83 them to be sorted with high purity using the multitarget dielectrophoresis activated cell sorter (MT-

84 erative diseases requires the development of multitarget-directed drugs (MTDs).

85 reported molecules designed according to the multitarget-directed ligand paradigm to exert combined a

86 for Alzheimer's disease, in this paper, the multitarget-directed ligand paradigm was applied to the

87 macological profile in the design of a novel multitarget-directed ligand that is able to exert not on

88 roidal anti-inflammatory drug carprofen as a multitarget-directed ligand that simultaneously inhibits

89 and in vitro evaluation of a novel series of multitarget-directed ligands (MTDL) displaying both nano

90 For years, the design of such multitarget-directed ligands (MTDLs) has been based on t

91 For years, the design of such multitarget-directed ligands (MTDLs) has been based on t

92 A series of multitarget-directed ligands (MTDLs) was designed by fun

93 2(3H)-one heterocycle, new resveratrol-based multitarget-directed ligands (MTDLs) were obtained.

94 or donepezil and diarylthiazole as potential multitarget-directed ligands for the treatment of Alzhei

95 Therefore, multitargeted disruption of the beta-catenin-TCF7L2-JMJD

96 binations whose selective synergy depends on multitarget drug activity.

97 the effector and interference moieties in a multitarget drug determines its use: selective killing o

98 P shows promising preclinical potential as a multitarget drug for the prevention and/or treatment of

99 t a reproducible "AI-to-clinic" paradigm for multitarget drug innovation in aging-related neurodegene

100 evelopment, the discovery of non-hydroxamate multitarget drugs against specific MMPs is of foremost i

101 anticancer drugs, combination therapies and multitarget drugs have been suggested in many studies, w

102 suggested in many studies, where the use of multitarget drugs is advantageous from a pharmacokinetic

103 An earlier design of multitarget drugs was confined to macromolecular reagent

104 senting an attractive opportunity to achieve multitarget drugs with synergic pharmacological effects.

105 ce approaches to the computational design of multitarget drugs.

106 involved in the generation of candidates as multitarget drugs.

107 peutic benefits are likely attributed to its multitargeted effects on cerebrovascular patency and int

108 NA target with very high specificity using a multitarget ELISA-based specificity assay.

109 -)-35, and (+/-)-36 with potent and balanced multitarget enzymatic profiles exhibited excellent effic

110 Multitarget FAAH/Cox blockade may provide a transformati

111 The new compounds are among the most potent multitarget FAAH/COX inhibitors reported so far in the l

112 linked to the ability of STX140 to act in a multitargeting fashion in vivo as a microtubule disrupto

113 n to the selective FGFR inhibitor BGJ398 and multitargeted FGFR inhibitor ponatinib.

114 estigated, such as telomerase, survivin, and multitarget fluorescence in situ hybridization, which ma

115 g complexes on p63 or NF-kappaB/Rel sites of multitarget gene promoters.

116 er 24 weeks of therapy, more patients in the multitarget group (45.9%) than in the intravenous cyclop

117 time to overall response was shorter in the multitarget group (difference, -4.1 weeks [CI, -7.9 to -

118 overall response incidence was higher in the multitarget group than in the intravenous cyclophosphami

119 minary mechanistic research of unprecedented multitargeting heterocyclic ferrociphenols bearing eithe

120 udy led to the identification of a promising multitarget hit compound (5b) exhibiting high hMAO B inh

121 timize the antitrypanosomatid profile of the multitarget hit compound B6 (1).

122 ly indirect targeting of HOXA9 expression or multitarget HOX/PBX protein/protein interaction inhibito

123 Our results indicate that a complex and multitargeted hsa-miRNA response occurs during CMV repli

124 IFN-gamma-induced class II transactivator, a multitarget immune modulator, resulting in increased ant

125 les are brain-penetrant and exhibit balanced multitargeted in vitro activity in the low muM range.

126 The result of such multitarget inhibition is potent inhibition of TB cell g

127 ion of a structure-activity relationship for multitarget inhibition.

128 nt and selective Bcr-Abl inhibition and with multitargeted inhibition of Bcr-Abl and Src family kinas

129 then metronomic chemotherapy, overlaid with multitargeted inhibition of PDGFR and VEGFR, gave comple

130 we describe MK-2461, a novel ATP-competitive multitargeted inhibitor of activated c-Met.

131 Besides, three more new multitarget inhibitors were identified by this virtual s

132 uses dynamic covalent chemistry to identify multitarget inhibitors.

133 aling how large-scale profiling can identify multitargeted inhibitors of specific, diverse kinases.

134 emia (T-ALL) samples and pave the way toward multitargeted JAK1 and JAK3 therapy in T-ALL.

135 incipal mechanisms of action of sorafenib, a multitarget kinase inhibitor approved for the treatment

136 es cancer cell invasion, while vandetanib, a multitarget kinase inhibitor, dose-dependently inhibits

137 that takes advantage of a well-characterized multitargeted kinase inhibitor describes a nongenetic ap

138 ted to determine whether the addition of the multitargeted kinase inhibitor midostaurin to intensive

139 The addition of the multitargeted kinase inhibitor midostaurin to standard c

140 Dasatinib is a novel, oral, multitargeted kinase inhibitor of BCR-ABL and SRC family

141 ne kinase inhibitors, including dasatinib (a multitargeted kinase inhibitor of BCR-ABL and Src family

142 Recently, the multitargeted kinase inhibitor sorafenib was shown to be

143 iruses, all of which can be amplified by the multitargeted kinase inhibitor sunitinib.

144 KW-2449 is a novel multitargeted kinase inhibitor that induces cytotoxicity

145 b is an orally bioavailable, small molecule, multitargeted kinase inhibitor that inhibits VEGF recept

146 hether the addition of midostaurin - an oral multitargeted kinase inhibitor that is active in patient

147 Dasatinib is a multitargeted kinase inhibitor that was recently approve

148 tion of a fluorine-18 analog of dasatinib, a multitargeted kinase inhibitor, are reported.

149 The efficacy of sorafenib, a multitargeted kinase inhibitor, in melanoma is still und

150 Our approach is based on using a multitargeted kinase inhibitor, SM1-71, as a tool compou

151 lled kinome regularization (KiR) to identify multitargeted kinase inhibitors (KIs) that abrogate CRPC

152 SRC inhibitors, dasatinib and bosutinib, are multitargeted kinase inhibitors.

153 these two compounds emerged to be promising multitarget lead candidates worthy of further pursuit.

154 These compounds emerge as promising safe multitarget ligands for the further development of a the

155 in the weight loss, we report a new class of multitarget ligands targeting the mentioned enzymes.

156 and monoamine oxidase B (MAO B), a series of multitarget ligands was properly designed by linking the

157 it as a lead compound in this novel class of multitarget ligands.

158 tors provides a new avenue for the design of multitarget ligands.

159 As an innovative strategy, multitargeting ligands (MTLs) were developed to achieve

160 d faster immunostaining protocols, and allow multitarget localization with primary IgGs from the same

161 work, we present an alternative system, the multitarget magnetic activated cell sorter (MT-MACS), wh

162 observed cytotoxic potency was ascribed to a multitarget mechanism of action accounting for hGAPDH in

163 GT has a multitarget mechanism of action: It is fungicidal and ba

164 l expansion in vivo and that this involves a multitarget mechanism that includes repression of IFN si

165 4503 alone is capable of regressing AML by a multitargeted mechanism and that the addition of bevaciz

166 ective in preventing obesity through various multitargeted mechanisms of weight loss.

167 ination used in the medulloblastoma European multitarget metronomic antiangiogenic trial (MEMMAT) giv

168 2.6 for both linear quadratic and single-hit multitarget models.

169 ive prospective application, we identified a multitarget-modulating profile of de novo designed molec

170 and complementary approach is the design of multitargeted modulators simultaneously addressing multi

171 hia coli polysaccharide K5 [K5-N,OS(H)] as a multitarget molecule highly effective in inhibiting VEGF

172 that K5-N,OS(H) represents an antiangiogenic multitarget molecule with potential implications for the

173 itable as a scaffold for the design of novel multitargeted molecules.

174 uding bioconjugates, bifunctional compounds, multitargeting molecules, chimeras, hybrids, engineered

175 acuity, motion direction discrimination, and multitarget motion comparison.

176 , after tryptic digestion, and quantified by multitarget nanoHPLC-HRMS analysis.

177 This work ultimately highlights the multitarget nature, fine structural tuning capacity, and

178 ctorial pathology and the development of new multitarget neuroprotective drugs is promising and attra

179 Multitarget nonsteroidal anti-inflammatory drug (NSAID)-

180 In vivo studies validating multitargeting of prostanoid receptors for achieving sup

181 Multitargeting of selected prostanoid receptors yielded

182 Using deep mutational scanning and multitarget optimization, we developed a germline-target

183 inase inhibitors (TKIs), even when these are multitargeted or applied in combination.

184 Here we report that BEZ235, a multitargeted pan-PI3K/dual-mTOR inhibitor, potently kil

185 The CDC developed a multitarget PCR assay to differentiate B. pertussis, B.

186 ity limitations might inhibit routine use of multitarget PCR for clinical diagnosis, focused testing

187 by using the discriminative features of this multitarget PCR.

188 species in 164 of 298 specimens tested with multitarget PCR; B. holmesii and Bordetella pertussis we

189 Of the 11 eyes subjected to PPV, the multitargeted PCR results for tuberculosis were positive

190 Consequently, it seems that multitargeted photoimmunotherapy should also be useful a

191 s hold important implications for the use of multitargeted PI3K inhibitors in the treatment of hemato

192 Vitreous fluid samples were subjected to multitargeted polymerase chain reaction (PCR) for a M. t

193 ase (sEH) and acetylcholinesterase (AChE), a multitarget profile to provide cumulative effects agains

194 agents, which can be explained by potential multitargeted properties.

195 ip studies that led to the identification of multitargeted prototypes with activities as MT-stabilizi

196 MgPa adhesion gene and the 16S rRNA gene, a multitarget real-time (MTRT) PCR for the detection of MG

197 A multitarget real-time PCR (MRT-PCR) for detection of Chl

198 A novel multitarget real-time PCR (RT-PCR) assay for the rapid i

199 A multitarget real-time PCR assay with three targets, incl

200 We have developed a multitarget real-time TaqMan PCR assay capable of rapidl

201 bination of oral sunitinib, a small molecule multitargeted receptor tyrosine kinase (RTK) inhibitor,

202 Sunitinib is a multitargeted receptor tyrosine kinase inhibitor approve

203 Sunitinib is an oral, multitargeted receptor tyrosine kinase inhibitor of the

204 SU11248, a multitargeted receptor tyrosine kinase inhibitor of VEGF

205 with solid malignancies were treated with a multitargeted receptor tyrosine kinase inhibitor resulti

206 ABT-869 (a multitargeted receptor tyrosine kinase inhibitor) inhibi

207 Sunitinib (ST), a multitargeted receptor tyrosine kinase inhibitor, has be

208 with solid malignancies were treated with a multitargeted receptor tyrosine kinase inhibitor, result

209 or sequential administration of sunitinib, a multitargeted receptor tyrosine kinase inhibitor.

210 Effects of 4 multitargeted receptor tyrosine kinase inhibitors on reg

211 or 8 and 90 revealed that both compounds are multitargeted receptor tyrosine kinase inhibitors with l

212 ccumulated that one mechanism for Gbetagamma multitarget recognition is through an intrinsically flex

213 type 1 infection and no cirrhosis, a 12-week multitargeted regimen of ABT-450/r-ombitasvir and dasabu

214 Treatment with the multitargeted regimen of ombitasvir-ABT-450/r and dasabu

215 RNA targets of multitargeted RNA-binding proteins (RBPs) can be studied

216 In conclusion, the use of this multitarget RT-PCR approach increases specificity, while

217 eak investigations were used to evaluate the multitarget RT-PCR assay.

218 SU11657 is a multitargeted selective inhibitor of class III/V recepto

219 The unusual multitarget selectivity of leucettines may account for t

220 ge epidemiologic study, we developed a fast, multitarget, sensitive, and specific assay named the Res

221 . bolletii isolates previously identified by multitarget sequencing.

222 Analyzed by the single-hit multitarget (SHMT) model, F1, F5, and F7, like camptothe

223 activated in most cancers and operate within multitarget signaling pathways.

224 ethylpyrazin-2-yl)methanimine oxide (6) is a multitarget small nitrone showing potent thrombolytic ac

225 s include simple and efficient production of multitarget-specific molecules in Escherichia coli, impr

226 We developed a model to determine whether a multitarget stool DNA (MT-sDNA) test that detects colore

227 ration, participants collected samples for a multitarget stool DNA test and 2 fecal immunochemical te

228 We compared a noninvasive, multitarget stool DNA test with a fecal immunochemical t

229 plasia were 0.72 (95% CI, 0.69-0.75) for the multitarget stool DNA test, 0.61 (95% CI, 0.58-0.64) for

230 nnial fecal immunochemical test, a triennial multitarget stool DNA test, and a triennial blood-based

231 A next-generation multitarget stool DNA test, including assessments of DNA

232 rsons at average risk for colorectal cancer, multitarget stool DNA testing detected significantly mor

233 testing, fecal immunochemical testing (FIT), multitarget stool DNA testing, flexible sigmoidoscopy wi

234 ography screening were greater than those of multitarget stool DNA.

235 ood test, the fecal immunochemical test, the multitargeted stool DNA test, and the methylated SEPT9 D

236 ome a suitable option for development of new multitarget strategies for inhibiting RAS-dependent tumo

237 successful case studies of already developed multitarget strategies involving CB2R, in this Perspecti

238 rylimidazoles provide tools to explore novel multitargeted strategies for AD and other neurodegenerat

239 ression can lead to the development of novel multitargeting strategies for intrahepatic cholangiocarc

240 A multitarget strategy is proposed to design penicillin-ba

241 We used a multitarget strategy to rationally design inhibitors cap

242 We developed a multitarget strategy to synthesize dual peptides simulta

243 By initially applying this multitarget strategy to the pressing problem of hormone-

244 A multitargeted strategy to treat the consequences of isch

245 s challenging, limiting their application in multitarget studies.

246 Multitarget synthetic strategies to access novel photoch

247 When the multitarget TaqMan assay (ISFtu2, 23kDa, and tul4) was c

248 sensitive and specific nature of this rapid multitarget TaqMan assay provides a valuable new tool th

249 t showed a modulation of activity during the multitarget task.

250 ising candidates for further optimization as multitarget therapeutic agents for neurodegenerative dis

251 pounds, promising for the design of original multitarget therapeutic agents for treating neurodegener

252 y as time elapses, we suggest a stepwise and multitarget therapeutic approach for SIRS and sepsis.

253 A multitargeted therapeutic approach using a bile acid seq

254 should encourage further development toward multitargeted therapeutic intervention in HDBC.

255 roof of concept in MaugOs for development of multitarget therapeutics that simultaneously target the

256 In this context, the development of single multitargeted therapeutics directed against two or more

257 we report a novel strategy in the design of multitargeted therapeutics for AD through dual inhibitio

258 aiming at the development of microRNA-based multitargeted therapeutics for AD.

259 ational combination of judiciously selected, multitarget therapies.

260 e the combination of additive or synergistic multitarget therapies.

261 y represent a novel target in the search for multitargeted therapies based on the HSP90 chaperone sys

262 This has spurred the development of multitargeted therapies, including small molecules that

263 vel specific molecular leukemic effector for multitarget therapy in p190-BCR-ABL-expressing acute lym

264 Multitarget therapy provides superior efficacy compared

265 We assessed whether multitarget therapy with enfuvirtide, 2 reverse-transcri

266 with HCV genotype 1 infection and cirrhosis, multitargeted therapy with the use of three new antivira

267 images from a phase II study of sunitinib, a multitargeted TKI.

268 Rational development of multitargeted TKIs for prostate cancer requires improved

269 ew process for ICIs, VEGF(R) inhibitors, and multitargeted TKIs, and 159 reports were selected for in

270 ost combinations with VEGF(R) inhibitors and multitargeted TKIs, exercising caution is recommended.

271 Our work supports the value of multitargeted tool compounds with well-validated polypha

272 targeted therapies rather than non-specific, multitargeted treatments.

273 Multitargeted tyrosine kinase inhibition has recently sh

274 n HIF-2alpha inhibitor in combination with a multitargeted tyrosine kinase inhibitor as a treatment o

275 SU11248 is an oral, selective multitargeted tyrosine kinase inhibitor currently in Pha

276 We conducted a phase II trial evaluating the multitargeted tyrosine kinase inhibitor lenvatinib in pa

277 FGFR2-mutated oral SCC who responded to the multitargeted tyrosine kinase inhibitor pazopanib.

278 The multitargeted tyrosine kinase inhibitor sorafenib is use

279 e therapy using FLT3 inhibitors, such as the multitargeted tyrosine kinase inhibitor sorafenib, impro

280 The novel multitargeted tyrosine kinase inhibitor sunitinib is use

281 Multitargeted tyrosine kinase inhibitor sunitinib reduce

282 Nilotinib, a recently approved multitargeted tyrosine kinase inhibitor targeting the BC

283 lity of sunitinib malate (SU11248), an oral, multitargeted tyrosine kinase inhibitor that blocks the

284 ial growth factor receptor 2, c-MET, and RET multitargeted tyrosine kinase inhibitor that has antiang

285 Sunitinib is a clinically approved multitargeted tyrosine kinase inhibitor that inhibits va

286 Sunitinib is an oral, multitargeted tyrosine kinase inhibitor that inhibits va

287 SU11657, a selective, oral, multitargeted tyrosine kinase inhibitor that targets FLT

288 Dasatinib (BMS-354825) is a multitargeted tyrosine kinase inhibitor that targets onc

289 In this study, we discovered a multitargeted tyrosine kinase inhibitor, compound 15a, w

290 Pazopanib, a multitargeted tyrosine kinase inhibitor, has recently be

291 lity and anticancer efficacy of sunitinib, a multitargeted tyrosine kinase inhibitor, in patients wit

292 Sunitinib malate is an oral multitargeted tyrosine kinase inhibitor, which has shown

293 staurin (PKC412; N-benzoylstaurosporin) is a multitargeted tyrosine kinase inhibitor, with demonstrat

294 ated whether a multimodal strategy combining multitargeted tyrosine kinase inhibitors (MTKIs) and mic

295 The multitargeted tyrosine kinase inhibitors Crizotinib and

296 neuregulin, whereas the off-target effect of multitargeted tyrosine kinase inhibitors may be mediated

297 n HIF-2alpha inhibitor, with cabozantinib, a multitargeted tyrosine-kinase inhibitor of VEGFR, c-MET,

298 Sunitinib, a multitargeted tyrosine-kinase inhibitor, which is approv

299 will compare advantages and disadvantages of multitarget versus combination therapies, discuss potent

300 standard." Our aim was to assess the use of multitarget versus single-target PCR for the diagnosis o